Skip Ribbon Commands
Skip to main content

Study Results

The CAVD’s Data & Materials Sharing Agreement states that the consortium whose members provided material used to generate the data from a standardized assay will then make reasonable efforts to disseminate such data to the broader scientific community. The following table provides links to the results from a number of studies conducted using standardized assays.

  
  
  
Neutralizing Activity of CD4bs bNAb N6 against HIV-1 Clade CMontefiori VIMCView Study Results
Phase 1 Evaluation of bNAb 10-1074Montefiori VIMCView Study Results
RV328 Plasma Neut Assays on Pub ID 328039Montefiori VIMCView Study Results
Analysis of neutralization activity in serum of immunized PGT121 knock-in mice.Montefiori VIMCView Study Results
Immunogenicity and antigenicity of variable loop optimized clade C gp140 Env trimersMontefiori VIMCView Study Results
Mouse 10E8-like bnAb Pre-Pilot PK StudyMontefiori VIMCView Study Results
Discovery & Characterization of bnAbsMontefiori VIMCView Study Results
Humoral response in an NHP vaccination model using RhCMV/SIV followed by homologous or heterologous challengeMontefiori VIMCView Study Results
Neutralization screening of B cell culture supernatants from leukepheresis samples from vacinees RV305_079 and RV305_018Montefiori VIMCView Study Results
Neutralization of Memory B-cell Supernatants from RV305 VacineesMontefiori VIMCView Study Results
Analysis of neutralization activity in the serum of human Ig knock-in mice immunized with Envelope-based immunogensMontefiori VIMCView Study Results
Screening for bNabs in HIV infected PatientsMontefiori VIMCView Study Results
ADCC activity of multi-specific antibodiesMontefiori VIMCView Study Results
Non-human primate challenge study comparing Vesicular Stomatitis Virus (VSV) vectors transiently and stably expressing the VSV G glycoproteinMontefiori VIMCView Study Results
Neutralization Activity of DH511 Lineage Chimeric HIV gp41 Distal MPER Broadly Neutralizing AntibodiesMontefiori VIMCView Study Results
Epitope Mapping and Development of Neutralization Breadth in a gp41 Distal MPER Broadly Neutralizing Antibody (bnAb) Clonal LineageMontefiori VIMCView Study Results
Neutralization Activity of MPER bnAb DH517 against a Panel of COT6.15 Env PseudovirusesMontefiori VIMCView Study Results
In vitro activity of HIV multi-specific antibodiesMontefiori VIMCView Study Results
A phase 2, open label study of the safety, antiretroviral activity and pharmacokinetics of 3BNC117 during a short analytical treatment interruption in HIV-infected subjectsMontefiori VIMCView Study Results
Neutralization of eCD4-Ig variants 1v34 and 2v26Montefiori VIMCView Study Results
Full-Length Single Chain (FLSC) Adjuvant Screening StudyMontefiori VIMCView Study Results
RV305 mAbs Differ in Strength and Breadth from RV144 mAbsMontefiori VIMCView Study Results
Evaluation and comparison of the safety and immunogenicity of different priming strategies combining NYVAC, DNA and gp120 protein vaccines in non-human primatesMontefiori VIMC, Koup VIMCView Study Results
Evaluation and comparison of the safety and immunogenicity of prime-boost regimens combining different poxvirus vector-based and gp120 protein vaccines in non-human primatesMontefiori VIMC, Koup VIMCView Study Results
A phase 1 study of the safety, PK and antiretroviral activity of 3BNC117mAb in humansMontefiori VIMC, Koup VIMCView Study Results
Studies to maximize immunogenicity by Env trimer stabilization and complement activationMontefiori VIMCView Study Results
Comparison of env protein binding characteristics for IgG antibodies generated in mice after immunization with CD4-independent variants of HIV-1 envelopesMontefiori VIMCView Study Results
Impact of IgG Subclass on Capacity to Mediate Neutralization of TH023.6Montefiori VIMC
Feb 2015_Development of bNAbs in HIV infectionMontefiori VIMCView Study Results
Immunogenicity of heterologous boost immunizations with MVA-CMDR, a modified vaccinia Ankara HIV-1 vaccine expressing Env gp 150/gag/pol, in HIV-uninfected volunteers previously immunized with DCVax-001 plus poly-ICLCMontefiori and Koup VIMCView Study Results
Evaluating the impact in nonhuman primates of using nano particle formulated TLR 4 and 7 agonists for enhancing humoral immunity against HIV specific envelope protein immunogens - a study conducted by the Pulandran laboratory.Montefiori VIMCView Study Results
Characterization of novel broadly neutralizing antibody LN01Montefiori VIMCView Study Results
Characterization of novel broadly neutralizing antibody LN01Montefiori VIMCView Study Results
RV305 vaccine regimen boosts RV144 plasma ADCC responsesMontefiori VIMCView Study Results
ART testing by MLV Neutralization AssayMontefiori VIMCView Study Results
Evaluation of TV1.C and 1086.C gp120s lots from Research and Development via Immunogenicity in Guinea PigsMontefiori VIMCView Study Results
Evaluation of subtype B and E gp120s via Immunogenicity in Guinea PigsMontefiori VIMCView Study Results
Evaluation on the quality of gp120-specific antibody responses elicited by different glycan processed gp120sMontefiori VIMCView Study Results
Targeting HIV-1 Env Gp140 to LOX-1 Elicits Immune Responses in Rhesus MacaquesMontefiori VIMC, Koup VIMCView Study Results
Targeting HIV-1 Env Gp140 to LOX-1 Elicits Immune Responses in Rhesus MacaquesMontefiori VIMC, Koup VIMCView Study Results
Rabbit Immunogenicity Study of Heterologous N7 Prime-Boost Immunization - RX2Montefiori VIMCView Study Results
Rabbit Immunogenicity Study of Heterologous N7 Prime-Boost Immunization - RX2Montefiori VIMCView Study Results
Neutralization assay using the MUC5AC at constant concentration of (0.5mg/ml) and serial dilution of HIV-1 antibody panelMontefiori VIMCView Study Results
Neutralization assay using the MUC5AC at constant concentration of (0.5mg/ml) and serial dilution of HIV-1 antibody panelMontefiori: VIMCView Study Results
CM244 neutralization activity of memory B cell culture supernatants and recombinant mAbs from an RV305 patient (PubID: RV305_094)Montefiori VIMCView Study Results
mAbs from a subject in RV305 Neutralize Tier 2 Virus CNE8Montefiori VIMCView Study Results
Neutralizing antibody responses and linear epitope specificity in RV305Montefiori VIMCView Study Results
Neutralization activity of antibodies Ab53042.1 and Ab530402.2, from an RV305 participant, tested against an expanded tier 2 virus panelMontefiori VIMCView Study Results
Test the breadth and potency of engineered bNAbsMontefiori VIMCView Study Results
Neutralization of sera derived from NHP Studies 204 and 205 (MPER-liposomes)Montefiori VIMCView Study Results
IAVI NHP study evaluating CDV and VSV vectors encoding the HIV envelope BG505Montefiori VIMC, Koup VIMCView Study Results
ADCC results: Rabbit Immuongencity Study of Heterologous N7 Prime-Boost Immunization- RX2Montefiori VIMCExploratory assays only
VRC 422: A study assessing effects of the adjuvants: alum, alum/TLR7 agonist, MF59 and polyIC on HIV TV1 gp140 immunity in nonhuman primatesMontefiori VIMCView Study Results
DNA-Protein Coimmunization to Increase Antibody PersistenceKoup VIMCView Study Results
(no title)Montefiori VIMCView Study Results
Screening for Neutralizing Antibody Breadth from Clade B US cohorts of suppressors and chronic progressorsMontefiori VIMCView Study Results
Immune responses to novel VSV chimeric viral vectors as potential vaccine candidatesMontefiori VIMCView Study Results
Head-to-head comparison of targeting HIV-1 Env gp140 to CD40 versus LOX-1 in combination with replication competent NYVAC-KC in Rhesus macaquesMontefiori VIMC, Koup VIMCView Study Results
Tier 1 and Tier 2 neutralization evaluation of plasma samples from 47 HIV+ individuals from an clinical HIV-1 observation cohort in Germany Montefiori VIMCView Study Results
Cytoplasmic tail modifications in HIV-1/89.6 Env can improve the neutralizing antibody responseMontefiori VIMCView Study Results
Monoclonal antibodies from elite controllers who exhibit strong neutralizating antibody breadthMontefiori VIMCView Study Results
Monoclonal antibodies from elite controllers who exhibit strong neutralizating antibody breadthMontefiori VIMCView Study Results
Cytoplasmic tail modifications in HIV-1/JRFL Env can improve the Env-specific antibody responseMontefiori VIMCView Study Results
Engineering Bispecific Antibodies to Enhance HIV-Neutralizing ActivityMontefiori VIMCView Study Results
Neutralization of plasma and recombinant mAbs from RV144/RV305 patientsMontefiori VIMCView Study Results
Neutralization of plasma and recombinant mAbs from RV144/RV305 patientsMontefiori VIMCView Study Results
QC of IgA antibodies from RV144 vaccine recipient clonal memory B cell culturesMontefiori VIMCView Study Results
Characterization of monoclonal antibodies from RV144 vaccine recipientsMontefiori VIMCView Study Results
Evaluating strategies to subvert self-tolerance as a suppression mechanism in the induction of 2F5-like MPER antibodiesMontefiori VIMCView Study Results
Neutralization profile of IgAsMontefiori VIMCView Study Results
NAb responses elicited by ChAd24, RhAd52, and RhAd35 vectors expressing 459C Env gp140, all followed by a 459C Env gp140/AS01B boostMontefiori VIMCView Study Results
Neutralizing Activity of bNAbs VRC07-523.LS, VRC13, CAP256.VRC26.25, and 10E8 against HIV-1 Clade C isolatesMontefiori: Ab VIMCView Study Results
Neutralizing Activity of bNAbs VRC07-523.LS, VRC13, CAP256.VRC26.25, and 10E8 against HIV-1 Clade C isolatesMontefiori VIMCView Study Results
Guinea pig immunizations comparing JFRL p140 or BG505 SOSIP trimers +/- incorporation to complement activating beta-glucan particlesMontefiori VIMCView Study Results
Mouse immunogenicity of an HIV envelope vaccine prime delivery with nucleoside modified mRNA complexed in lipid nanoparticlesMontefiori VIMCView Study Results
Linear Ab epitope mapping with mouse sera following immunization with alum-adjuvanted, stabilized 1086C and/or JRFL and a Complement ActivatorMontefiori VIMCView Study Results
Neutralization Breadth and Coverage of monoclonal antibodies PGT121, PGT145, and PGDM1400 Against Clade C and Global Virus PanelsMontefiori VIMCView Study Results
Comparison of affinity and neutralizing capacity of unlabeled and labeled broadly neutralizing antibodies to HIV-1 EnvelopeMontefiori VIMCView Study Results
Functional antibody and T cell responses in samples obtained from MUCOVAC02 human clinical trialKoup VIMCView Study Results
Linear peptide epitope mapping for two NHP studies (VAC1003 and Schedule 227) using gp140 trimersMontefiori VIMCView Study Results
Screening for Neutralizing Antibody Breadth in association with HIV-specific CD4 T cell responsesMontefiori VIMCView Study Results
Phase I trial of human anti-DEC-205 p24 mAb plus poly ICLC in healthy volunteersKoup VIMCView Study Results
Improved anti-HIV-1 reagentsMontefiori VIMCView Study Results
PGT mAb screening studyMontefiori VIMCView Study Results
NHP Study P162 - a recapitulation of RV144 in NHP, with alternate adjuvants and boosting with differing protein constructsKoup VIMCView Study Results
Neutralization and Binding Data for 4 Germline Versions of bNAbs from HIV-Infected PatientsMontefiori VIMCView Study Results
Mouse Immunogenicity Study of CD4-independent Env R3AMontefiori VIMCView Study Results
Assessment of neutralization activity of antibody fragments against HIV entryMontefiori VIMCView Study Results
Mouse immunizations using alum-adjuvanted, stabilized 1086C and/or JRFL and a Complement ActivatorMontefiori VIMCView Study Results
Immunogenicity of cross-linked BG505 trimerMontefiori VIMCView Study Results
Neutralization of SHIVs by monoclonal antibodies isolated from RV144 PBMCs and produced as recombinant mAbsMontefiori VIMCView Study Results
Neutralization characteristics for sera from NHP Study 64 (bivalent vs. pentavalent gp120 boosts following 2X ALVAC priming)Montefiori VIMCView Study Results
Microarray analysis of NHP Study #38.2: IV-infusion of the non-neutralizing gp41-binding antibody 7B2Koup VIMCView Study Results
Microarray signatures of the RV144 prime/boost regimen in non-human primatesMontefiori VIMC, Koup VIMCView Study Results
Study to determine whether Env immunogen binding to human CD4 affects immunogenicity - Mouse Immunogenicity Study 7 Revised (MU7R)Montefiori VIMCView Study Results
Mixed HIV-1 Envelope Protein Vaccination Yields Superior Antibody Binding Compared to Clonal or Sequential Delivery in RabbitsMontefiori VIMCView Study Results
HIV-1 neutralization responses in chronically infected individualsMontefiori VIMCView Study Results
The neutralization activities and epitope mapping of Man9 Env (from Pichia pastoris) and CHO-Env immunized seraMontefiori VIMCView Study Results
Epitope mapping of rabbit sera induced by either DNA prime protein boost or co-delivery of DNA and protein vaccinesMontefiori VIMCView Study Results
Neutralization activities induced by Man5 Env (from Pichia pastoris) and CHO-EnvMontefiori VIMCView Study Results
1 - 100Next
For general questions about the CAVD or the content of the these pages, please contact alliance.management@cavd.org.
For technical issues with the website, please contact portalsupport@cavd.org.